A Prospective Study on Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With HR-positive and HER2-negative, Secondary Endocrine-resistant, Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Catequentinib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 04 Jun 2024 Results (n=30) assessing efficacy and safety of the combined regimen in pts with HR-positive and HER2-negative, previously AI treated, locally advanced or metastatic breast cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 24 Oct 2023 Results (n=22) assessing safety and efficacy of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor presented at the 48th European Society for Medical Oncology Congress
- 15 Oct 2021 New trial record